Renal Denervation Market Analysis | 2022-2028

Market Insights

"The global renal denervation market is expected to grow at a CAGR of 31.6% during the forecast period. The market was valued at US$ 600.0 million in 2021 and will reach US$ 5,396.4 million by 2028."

Want to get a free Sample? Register Here

Renal denervation is a minimally invasive catheter-based treatment that is used to treat resistant hypertension. In the process, radiofrequency ablation is used to burn nerves in the renal arteries. If pharmacological treatment does not result in relief, this procedure is usually used to achieve better results. The nerves in the renal artery wall are removed using high-frequency pulses or ultrasound.

It lowers blood pressure by reducing the activity of the sympathetic kidneys. The market growth is challenged by the risks associated with post-surgery infection, the high cost of renal denervation techniques, the lack of a skilled workforce, changes in renal anatomy and long-term follow-up procedures.

Key Players

Key players operating in the global renal denervation market include:

• Medtronic (US)
• Boston Scientific Corporation (US)
• Brattea (China)
• Abbott (US)
• ReCor Medical, Inc. (US)
• Johnson & Johnson Private Limited (US)
• Terumo Corporation (Japan)
• Mercator MedSystems, Inc. (US)
• Ablative Solutions, Inc. (US)
• SympleSurgical Inc. (US)
• SoniVie (Israel)
• Kona Medical Inc. (U.S.)
• Renal Dynamics Limited (U.K.)
• Otsuka Medical Devices Co., Ltd. (Tokyo)

Market Dynamics

Benefits of Renal Denervation Therapy Devices:

Renal denervation therapy has shown positive results in reducing hypertension. Therefore, renal denervation therapies offer benefits such as higher safety, shorter treatment times, and long-lasting effects among others, resulting in driving the market growth. Also, technological advancements in renal denervation devices contribute positively towards the market growth during the study period.

The development of catheter-based interventions to remove renal nerves has shown positive and effective results in patients suffering from hypertension by resisting hypertensive symptoms. Moreover, catheter-based procedures are comparatively safer for the patients and facilitate the denervation of selected nerves.

Rising Prevalence of Hypertension:

Hypertension is very common due to many factors such as depression, stress, co-morbid conditions, and several other factors. Renal denervation therapy has always shown a positive result in managing hypertension. According to the Centers for Disease Control and Prevention (CDC), in 2020, more than 670,000 deaths in the United States had hypertension as a primary cause; and about half of the adults in the country have hypertension. Hence, a significant prevalence of hypertension contributed towards the growth of the renal denervation market over the forecast period.

COVID-19 Impact:

The novel coronavirus (COVID-19) rapidly spread across the globe in the year 2019. This spread was responsible for an enormous impact on people. Due to the pandemic, production across industries halted and devices used in managing and curing renal denervation were no exception, owing to worldwide lockdowns at different levels and at different times.

Vaccination and treatment of patients have led to the reopening of manufacturing facilities, resulting in the active operation of renal denervation companies at their full-scale capacities, hence it is anticipated that the market will fully recover by the start of 2023.

Segment Analysis

Product Insights

"Simplicity Renal Denervation System segment accounted for the largest market share."

Simplicity Renal Denervation System accounted for the largest share of the global renal denervation market in 2020. This system is being used to treat hypertension as it delivers low-level radiofrequency energy and reduces the risk of radiation on body tissues due to high-level radiofrequency. It also offers a minimally invasive procedure to treat excessive hypertension.

In the global renal denervation industry, radiofrequency was the most frequently used technology and it was the key contributing segment in 2020. Radiofrequency renal denervation is an effective way to control resistant hypertension, and a one-time procedure is enough to lower blood pressure levels for up to two years.

Regional Trends

"North America accounted for the largest market share."

The North American renal denervation market dominated the global marketplace owing to a high number R&D activities coupled with the changing lifestyle of the population. Moreover, Asia-Pacific renal denervation market will grow at the highest growth rate during the forecast period, due to the rising number of cases related to diabetes and obesity along with a rising number of drug-resistant hypertension cases.

Europe renal denervation market has accounted for a significant share in recent times. The regional share is attributed to the early start of this technology in the region along with the most of the devices in this market have a CE mark approval and are available for commercial purposes in the region.

The Asia-Pacific renal denervation market is estimated to grow at a high CAGR. The regional growth is attributed to the increase in awareness about the use of advanced technologies such as renal denervation systems, the presence of ample growth opportunities in terms of unmet medical needs for the treatment of hypertension and the high prevalence rate of resistant hypertension.

Want to get a free sample? Register Here

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market.

What deliverables will you get in this report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

Recent Developments

The global renal denervation market competitive landscape provides details by competitor. Companies are adopting various competitive strategies to withhold strong foothold in the market. For instance:

In April 2021, Medtronic partnered with Surgical Theater to integrate the StealthStation S8 Surgical Navigation System with Surgical Theater'sSyncAR Augmented Reality technology. This technology will help neurosurgeons use real-time AR technology to improve visualization during difficult cranial surgery.

In April 2021, Brattea, a renal denervation medical technology company based in China, announced the completion of US$ 20 million Series B+ financing led by Kuanping Capital, a healthcare private equity fund.

In December 2020, SoniVie, has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the TIVUS System for renal artery denervation for the treatment of resistant hypertension.